BR112018011687A2 - terapia de gene para tratar hipercolesterolemia familiar - Google Patents
terapia de gene para tratar hipercolesterolemia familiarInfo
- Publication number
- BR112018011687A2 BR112018011687A2 BR112018011687A BR112018011687A BR112018011687A2 BR 112018011687 A2 BR112018011687 A2 BR 112018011687A2 BR 112018011687 A BR112018011687 A BR 112018011687A BR 112018011687 A BR112018011687 A BR 112018011687A BR 112018011687 A2 BR112018011687 A2 BR 112018011687A2
- Authority
- BR
- Brazil
- Prior art keywords
- gene therapy
- familial hypercholesterolemia
- raav
- treat familial
- ldl
- Prior art date
Links
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 title 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 title 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 title 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 101150102415 Apob gene Proteins 0.000 abstract 1
- 101710095342 Apolipoprotein B Proteins 0.000 abstract 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 abstract 1
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 230000001925 catabolic effect Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 210000003462 vein Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Abstract
composições e regimes úteis na redução de um ou mais de: colesterol ldl, colesterol total e / ou triglicerídeos em jejum em um indivíduo e/ou modificação da taxa catabólica fracional (fcr) da apolipopro-teína b (apob) de ldl desde a linha de base a um ponto do tempo selecionado após a administração do raav são fornecidos. o método envolve a administração ao indivíduo humano através de uma veia periférica por infusão de uma suspensão de vírus adeno-associado recombinante deficiente de replicação (raav).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562266383P | 2015-12-11 | 2015-12-11 | |
US201562269440P | 2015-12-18 | 2015-12-18 | |
PCT/US2016/065984 WO2017100682A1 (en) | 2015-12-11 | 2016-12-09 | Gene therapy for treating familial hypercholesterolemia |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018011687A2 true BR112018011687A2 (pt) | 2018-12-04 |
Family
ID=57794341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018011687A BR112018011687A2 (pt) | 2015-12-11 | 2016-12-09 | terapia de gene para tratar hipercolesterolemia familiar |
Country Status (14)
Country | Link |
---|---|
US (2) | US10889832B2 (pt) |
EP (2) | EP3400304B1 (pt) |
JP (2) | JP7328760B2 (pt) |
KR (1) | KR20180113990A (pt) |
CN (2) | CN115957350A (pt) |
AU (2) | AU2016366560A1 (pt) |
BR (1) | BR112018011687A2 (pt) |
CA (1) | CA3008142A1 (pt) |
CO (1) | CO2018007165A2 (pt) |
ES (1) | ES2921450T3 (pt) |
IL (2) | IL259850B2 (pt) |
MA (1) | MA43570A (pt) |
MX (1) | MX2018007080A (pt) |
WO (1) | WO2017100682A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3919508A1 (en) | 2014-04-25 | 2021-12-08 | The Trustees of The University of Pennsylvania | Ldlr variants and their use in compositions for reducing cholesterol levels |
EP3400304B1 (en) | 2015-12-11 | 2022-04-06 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating familial hypercholesterolemia |
WO2018022511A1 (en) | 2016-07-25 | 2018-02-01 | The Trustees Of The University Of Pennsylvania | Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof |
US11554147B2 (en) * | 2017-02-20 | 2023-01-17 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating familial hypercholesterolemia |
JP7384797B2 (ja) | 2017-11-30 | 2023-11-21 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ムコ多糖症iiib型のための遺伝子療法 |
WO2020132155A1 (en) * | 2018-12-20 | 2020-06-25 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating familial hypercholesterolemia |
BR112023015303A2 (pt) | 2021-02-01 | 2023-11-14 | Regenxbio Inc | Método para tratar doença cln2 devido a deficiência de tpp1 em um sujeito |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
US6548286B1 (en) | 1997-04-14 | 2003-04-15 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
EP1080218A1 (en) | 1998-05-27 | 2001-03-07 | University of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient |
AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
ES2478635T3 (es) | 1999-08-09 | 2014-07-22 | Targeted Genetics Corporation | Incremento de la expresión de una secuencia de nucleótidos heteróloga monocatenaria de vectores virales recombinantes diseñando la secuencia de modo que forma pares de bases intracatenarios |
ATE438414T1 (de) | 2000-06-01 | 2009-08-15 | Univ North Carolina | Verfahren und zusammensetzungen zur kontrollierter abgabe von rekombinant parvovirus vektoren |
ES2258601T3 (es) | 2001-11-13 | 2006-09-01 | The Trustees Of The University Of Pennsylvania | Un metodo para la identificacion de las secuencias desconocidas del virus adeno-asociado (vaa) y un kit para el metodo. |
EP3517134B1 (en) | 2001-12-17 | 2024-01-17 | The Trustees of the University of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences, vectors containing same and uses therefor |
US20070015238A1 (en) | 2002-06-05 | 2007-01-18 | Snyder Richard O | Production of pseudotyped recombinant AAV virions |
CN1856576B (zh) | 2003-09-30 | 2011-05-04 | 宾夕法尼亚州立大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
EP2359865B1 (en) | 2005-04-07 | 2013-10-02 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
WO2006132118A1 (ja) | 2005-06-09 | 2006-12-14 | Matsushita Electric Industrial Co., Ltd. | 振幅誤差補償装置及び直交度誤差補償装置 |
DE602007004712D1 (de) | 2006-02-24 | 2010-03-25 | Kenergy Inc | Klasse-e-funkfrequenz-leistungsverstärker mit rückmeldungssteuerung |
EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
KR101010352B1 (ko) | 2008-05-30 | 2011-01-25 | 삼성중공업 주식회사 | 전력 제어 장치 및 방법 |
CA2751266A1 (en) * | 2009-01-29 | 2010-08-05 | Krystof Bankiewicz | Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders |
WO2011020118A1 (en) * | 2009-08-14 | 2011-02-17 | Theramind Research, Llc | Methods and compositions for treatment of tuberous sclerosis complex |
ES2680915T3 (es) * | 2010-01-28 | 2018-09-11 | The Children's Hospital Of Philadelphia | Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica |
US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
AU2011238708B2 (en) | 2010-03-29 | 2016-02-11 | The Trustees Of The University Of Pennsylvania | Pharmacologically Induced Transgene Ablation system |
JP2014519848A (ja) | 2011-06-20 | 2014-08-21 | ジェネンテック, インコーポレイテッド | Pcsk9結合ポリペプチドと使用方法 |
FR2977562B1 (fr) | 2011-07-06 | 2016-12-23 | Gaztransport Et Technigaz | Cuve etanche et thermiquement isolante integree dans une structure porteuse |
EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
EP3536712B1 (en) | 2011-09-16 | 2023-05-31 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) |
AU2013221212B2 (en) * | 2012-02-17 | 2018-08-09 | The Children's Hospital Of Philadelphia | AAV vector compositions and methods for gene transfer to cells, organs and tissues |
DK2954051T3 (da) | 2013-02-08 | 2019-07-08 | Univ Pennsylvania | Modificeret kapsid til genoverførsel til behandling af nethinden |
WO2014127196A1 (en) * | 2013-02-15 | 2014-08-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Aav8 retinoschisin expression vector for treating x-linked retinoschisis |
WO2015012924A2 (en) | 2013-04-29 | 2015-01-29 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof |
JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
EP3919508A1 (en) | 2014-04-25 | 2021-12-08 | The Trustees of The University of Pennsylvania | Ldlr variants and their use in compositions for reducing cholesterol levels |
EP4215605A1 (en) | 2015-12-11 | 2023-07-26 | The Trustees of The University of Pennsylvania | Scalable purification method for aav8 |
EP3400304B1 (en) | 2015-12-11 | 2022-04-06 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating familial hypercholesterolemia |
US11554147B2 (en) | 2017-02-20 | 2023-01-17 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating familial hypercholesterolemia |
-
2016
- 2016-12-09 EP EP16825936.4A patent/EP3400304B1/en active Active
- 2016-12-09 KR KR1020187019657A patent/KR20180113990A/ko not_active Application Discontinuation
- 2016-12-09 EP EP22165782.8A patent/EP4085934A1/en active Pending
- 2016-12-09 WO PCT/US2016/065984 patent/WO2017100682A1/en active Application Filing
- 2016-12-09 IL IL259850A patent/IL259850B2/en unknown
- 2016-12-09 IL IL303850A patent/IL303850A/en unknown
- 2016-12-09 CA CA3008142A patent/CA3008142A1/en active Pending
- 2016-12-09 CN CN202211286244.1A patent/CN115957350A/zh active Pending
- 2016-12-09 AU AU2016366560A patent/AU2016366560A1/en not_active Abandoned
- 2016-12-09 MX MX2018007080A patent/MX2018007080A/es unknown
- 2016-12-09 ES ES16825936T patent/ES2921450T3/es active Active
- 2016-12-09 US US16/060,409 patent/US10889832B2/en active Active
- 2016-12-09 CN CN201680081580.9A patent/CN109121421B/zh active Active
- 2016-12-09 BR BR112018011687A patent/BR112018011687A2/pt active Search and Examination
- 2016-12-09 JP JP2018530566A patent/JP7328760B2/ja active Active
- 2016-12-09 MA MA043570A patent/MA43570A/fr unknown
-
2018
- 2018-07-09 CO CONC2018/0007165A patent/CO2018007165A2/es unknown
-
2020
- 2020-11-17 US US16/950,272 patent/US20210285013A1/en not_active Abandoned
-
2022
- 2022-01-11 JP JP2022002190A patent/JP2022050575A/ja active Pending
-
2023
- 2023-03-16 AU AU2023201657A patent/AU2023201657A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3008142A1 (en) | 2017-06-15 |
MX2018007080A (es) | 2018-11-12 |
IL303850A (en) | 2023-08-01 |
CN109121421A (zh) | 2019-01-01 |
WO2017100682A1 (en) | 2017-06-15 |
JP2022050575A (ja) | 2022-03-30 |
IL259850B1 (en) | 2023-07-01 |
JP2019504003A (ja) | 2019-02-14 |
AU2016366560A1 (en) | 2018-06-28 |
ES2921450T3 (es) | 2022-08-25 |
EP3400304A1 (en) | 2018-11-14 |
EP3400304B1 (en) | 2022-04-06 |
JP7328760B2 (ja) | 2023-08-17 |
US20210285013A1 (en) | 2021-09-16 |
EP4085934A1 (en) | 2022-11-09 |
US20190002917A1 (en) | 2019-01-03 |
AU2023201657A1 (en) | 2023-06-15 |
KR20180113990A (ko) | 2018-10-17 |
CO2018007165A2 (es) | 2018-07-19 |
IL259850A (en) | 2018-07-31 |
MA43570A (fr) | 2018-11-14 |
CN115957350A (zh) | 2023-04-14 |
IL259850B2 (en) | 2023-11-01 |
US10889832B2 (en) | 2021-01-12 |
CN109121421B (zh) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018011687A2 (pt) | terapia de gene para tratar hipercolesterolemia familiar | |
EA201891142A1 (ru) | Контроль клеточных окислительно-восстановительных уровней | |
PH12017501934A1 (en) | Methods for treating or preventing migraine headache | |
BR112018071200A2 (pt) | terapia genética para o tratamento da hemofilia a | |
CO2018007203A2 (es) | Focalización de péptidos para dirigir virus adenoasociados (aavs) | |
MY184586A (en) | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses | |
EA201890864A1 (ru) | Композиции и способы для ингибирования генной экспрессии лпа | |
NZ726316A (en) | Adenoassociated virus vectors for the treatment of lysosomal storage disorders | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
BR112017013599A2 (pt) | composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras. | |
BR112017019738A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
PE20150163A1 (es) | Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav | |
EA201990558A3 (ru) | Доставка нацеленных на экзон 2 полинуклеотидных конструкций u7snrna при помощи рекомбинантного аденоассоциированного вируса | |
PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
BR112018008601A2 (pt) | composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer | |
BR112017008962A2 (pt) | proteínas de fusão inibidoras de c1 esterase e usos das mesmas | |
WO2014025771A3 (en) | Methods and compositions for inactivating enveloped viruses | |
BR112017019728A2 (pt) | combinações e formulações de dose fixa compreendendo etc1002 e uma ou mais estatinas e método para tratar ou reduzir o risco de doença cardiovascular | |
EA201991447A1 (ru) | Снижение вязкости фармацевтических составов | |
EA201791898A1 (ru) | Новые антитела, связывающиеся с tfpi, и содержащая их композиция | |
BR112017019358A2 (pt) | combinações e formulações de dose fixa compreendendo etc1002 e ezetimiba e métodos de tratamento ou redução do risco de doença cardiovascular | |
EA202091712A1 (ru) | МОДИФИЦИРОВАННЫЙ КАПСИДНЫЙ БЕЛОК rAAV ДЛЯ ГЕННОЙ ТЕРАПИИ | |
MX2017014095A (es) | Uso de cd24 para disminuir los niveles de colesterol de las lipoproteinas de baja densidad. | |
CO2018003960A2 (es) | Virus adeno-asociado recombinante que comprende un ácido nucleico galgt2 | |
BR112018008911A2 (pt) | composições compreendendo vetores lentivirais que expressam il-12 e métodos de uso das mesmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |